The FDA has placed a hold on the Investigational New Drug (IND) application for DNL919, indicating they will provide an official clinical hold letter to Denali Therapeutics in approximately 30 days. Denali had hoped to begin fist-in-human clinical trials for its therapeutic DNL919, under development for the treatment of Alzheimer’s disease (AD).
Log in met Medi-Access
Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen
FDA places Alzheimer’s therapeutic IND Application on hold
InPharm.com | Geplaatst op 17.01.2022 11:40